Treatment of intracerebral glioblastomas with G422 tumour cell vaccine in a mouse model

Journal of International Medical Research

Volumn 36, Issue 2, 2008, Pages 308-313

  Ma, Y H ^a   Yu, J B ^a   Yao, H P ^a   Zhan, R Y ^a   Zheng, Jie Sheng ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

B7 1; Cytotoxic T lymphocytes; Glioblastoma; Immunotherapy; Interferon ; Intracerebral tumour isografts; Tumour vaccine

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; BETA GALACTOSIDASE; GAMMA INTERFERON; TUMOR CELL VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL BASED GENE THERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; DRUG FORMULATION; FEMALE; GLIOBLASTOMA; HUMORAL IMMUNITY; ISOGRAFT; MOUSE; NONHUMAN; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM;

EID: 42049116908     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600213     Document Type: Article

References (15)

1. Mourad PD, Farrell L, Stamps LD, et al: Why cire systemic glioblastoma metastases rare? Systemic and cerebral growth of mouse glioblastoma. Surg Neurol 2005; 63: 511-519.
2. Tang J, Flomenberg P, Harshyne L, et al: Glioblastoma patients exhibit circulating turnor-specific CD8+ T cells. Clin Cancer Res 2005; 11: 5292-5299.
3. Costello RT, Gastaut JA, Olive D: Mechanisms of tumor escape from immunologic response. Rev Med Interne 1999; 20: 579-588.
4. Ahmad M, Rees RC, Ali SA: Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 2004; 53: 844-854.
5. Allison JP: CD28-B7 interactions in T-cell activation. Curr Opin Immunol 1994; 6: 414-419.
6. Tatsumi T, Takehara T, Katayama K, et al: Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma. Hepatology 1997, 25: 1108-1114.
7. Gimmi CD, Freeman GJ, Gribben JG, et al: Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 1993; 90: 6586-6590.
8. Morioka J, Kajiwara K, Yoshikawa K, et al: Vaccine therapy for murine glioma using tumor cells genetically modified to express B7.1. Neurosurgery 2004, 54: 182-189.
9. Read SB, Kulprathipanja NV, Gomez GG, et al: Human alloreactive CTL interactions with gliomos and with those having upregulated HLA expression from exogenous IFN-γ or IFN-γ gene modification. J Interferon Cytokine Res 2003; 23: 379-393.
10. Tao G, Hu J, Zou H, et al: Therapeutic antitumor response to cervical cancer in mice immunized with U14 vaccines transfected with costimulatory B7 gene. Chin Med J (Engl) 2001; 114: 623-627.
11. Zhang L, Mi J, Yu Y, et al: IFN-γ gene therapy by intrasplenic hepatocyte transplantation: a novel strategy for reversing hepatic fibrosis in Schistosoma japonicum-infected mice. Parasite Immunol 2001; 23: 11-17.
12. Wetzler M, Tolpaz M, Van Etten RA, et al: Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest 1993; 92: 1925-1939.
13. Yang S, Tsang KY, Schlom J: Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells. Clin Cancer Res 2005; 11: 5603-5615.
14. + tumor responsive T cells after immunization with tum- versus tum+ rat glioma. Cell Immunol 1995, 165: 225-233.
15. Henning T, Kraus M, Brischwein M, et al: Relevance of tumor microenvironment for progression, therapy and drug development. Anticancer Drugs 2004; 15: 7-14.